Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03311204




Registration number
NCT03311204
Ethics application status
Date submitted
11/10/2017
Date registered
17/10/2017

Titles & IDs
Public title
The Effect of Eyelid Margin Debridement on Contact Lens Discomfort
Scientific title
The Effect and Duration of Efficacy of Eyelid Margin Debridement on Signs and Secretions of Eyelids, Tear Film and Discomfort in Contact Lens Wearers
Secondary ID [1] 0 0
UNewSouthwales
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Contact Lens Discomfort 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - BlephEx
Other interventions - Lid Hygenix

Experimental: Microblepharon Exfoliation - This treatment is provided using BlephEx tool from Optimed Pty Ltd.

Experimental: Eyelid cleansing using Lid Hygenix - Foam-based hypoallergenic cleanser used as a control treatment in this study.


Treatment: Devices: BlephEx
BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.

Other interventions: Lid Hygenix
Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
Intervention code [1] 0 0
Treatment: Devices
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Lid Wiper Epitheliopathy
Timepoint [1] 0 0
5 minutes
Secondary outcome [1] 0 0
Discomfort Rating - CLDEQ-8 Questionnaire
Timepoint [1] 0 0
5 minutes
Secondary outcome [2] 0 0
End of the Day Discomfort Rating
Timepoint [2] 0 0
30 minutes
Secondary outcome [3] 0 0
Tear Analysis
Timepoint [3] 0 0
15 minutes
Secondary outcome [4] 0 0
Meibum Analysis
Timepoint [4] 0 0
10 minutes
Secondary outcome [5] 0 0
Meibography
Timepoint [5] 0 0
5 minutes
Secondary outcome [6] 0 0
Demodex Infestation
Timepoint [6] 0 0
15 minutes
Secondary outcome [7] 0 0
Lid Microbiota
Timepoint [7] 0 0
5 minutes
Secondary outcome [8] 0 0
LipiView Interferometry
Timepoint [8] 0 0
10 minutes
Secondary outcome [9] 0 0
Lid Sensitivity
Timepoint [9] 0 0
5 minutes
Secondary outcome [10] 0 0
Tear Osmolarity
Timepoint [10] 0 0
5 minutes

Eligibility
Key inclusion criteria
* Age of 18 years or above
* Understand their rights as a research subject
* Willing and able to sign a statement of informed consent
* Normal ocular status, defined as a minimum of 20/40 visual acuity in each eye; clear corneas without scarring, opacities, or vascularization, as determined by biomicroscopic examination
* Normal external examination
* Normal puncta without punctal plugs
* Ability to cooperate with the required procedures of diagnostic agent installation, eyelid eversion, and examination.
* Contact lens wearers who have worn lenses for at least 6 months, used contact lenses for 3 weeks before the evaluation visit and used these lenses at least four times a week. These contact lens wearers will be on daily wearing modality, where the subject is supposed to wear it for at least for 6 hours, only during the day and remove the lenses during sleep.
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Any ocular or systemic disease that might influence the tear film and especially subjects with a history of episodes of epilepsy.
* Subjects with eyelid inflammation of more than grade 2 will be excluded from the study as they need therapeutic intervention.
* All conjunctival abnormalities, including pingueculae greater than 1 mm in diameter, location closer than 2 mm to the limbus, or elevated more than 0.2 mm
* All forms of conjunctivitis, including allergic conjunctivitis
* Fluorescein corneal staining of grade 2 or more, after a single installation of non-preserved fluorescein solution followed by examination 1 minute after installation
* Current ocular infection or treatment of such infections with ocular or systemic medications
* Current use of any prescription or non-prescription ocular or systemic medications, including antihistamines
* Use of artificial tear preparations during the period 2 hours before the examination
* Use of any ocular ointment during the 3 days before the examination
* Any history of ocular surgery

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Crossover
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2018
Sample size
Target
Accrual to date
Final
42
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
University of New South Wales - Kensington
Recruitment postcode(s) [1] 0 0
2152 - Kensington

Funding & Sponsors
Primary sponsor type
Other
Name
The University of New South Wales
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mark Willcox, D Sc
Address 0 0
University of New South Wales
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
All participants will be given a unique study identification code. Data will be de-identified at the time of collection such that only patient initials and a study identification number will be used to identify the data for each patient. Any data included in reports, publications or presented at meetings will be provided in the form of group responses or study identity numbers, such that the participants cannot be identified. Personal and health information (either identifiable or potentially identifiable) about individuals will not be disclosed to any external parties without the individual's consent unless required by law. The unique study identification code can be broken by the research team if required (re-identifiable).


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03311204